- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT04893187
A Phase 1 Study of SSS17 in Healthy Subjects.
A Phase 1 Study to Evaluate the Tolerance, Safety, Pharmacokinetics and Pharmacodynamics of Oral Administration of SSS17 in Chinese Healthy Adult Subjects With Single and Multiple Dose Escalation and the Effect of Food on the Pharmacokinetics of SSS17.
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
The study will enroll healthy volunteers from a single academic medical center in China. All participants will be informed about the study and potential risks and required to provide written informed consent prior to undergoing study-related procedures.The study will be divided into 3 parts.
Part 1: Subjects will be allocated 2:8 to receive placebo or SSS17(it was only 2:2 in 5mg dose group),which will be administered by oral route with single dose. At each dose, tolerability, safety, PK and PD characteristics will be investigated.
Part 2: Subjects will be allocated 2:8 to receive placebo or SSS17, which will be administered by oral route with multiple dose. At each cohort,tolerability, safety, PK and PD characteristics will be investigated.
Part 3: The subjects will receive two cycles of treatment, one is given on an empty stomach, the other is given after a high-fat meal, with an interval of 15 days.
Typ studiów
Zapisy (Oczekiwany)
Faza
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Director Li
- Numer telefonu: 18028886429
- E-mail: 747560265@qq.com
Kopia zapasowa kontaktu do badania
- Nazwa: Professor Fang, Ph.D
- Numer telefonu: 13701165926
- E-mail: fygk7000@163.com
Lokalizacje studiów
-
-
Guangdong
-
Guangzhou, Guangdong, Chiny, 510700
- Rekrutacyjny
- The Fifth Affiliated Hospital of Guangzhou Medical University
-
Kontakt:
- Yi Fang, Ph.D
- Numer telefonu: 13701165926
- E-mail: fygk7000@163.com
-
Kontakt:
- Yongmei Li, Ph.D
- Numer telefonu: 13640691018
- E-mail: Liyongmei_gz@126.com
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Chinese healthy adult subjects aged 18-45 years (including the boundary value) at the time of signing the informed consent were male and female;
- In the screening period, the weight of male subjects was more than or equal to 50.0 kg; Female weight ≥ 45.0 kg; Body mass index (BMI) ranged from 19.0 kg / m2 to 26.0 kg / m2 (including boundary value); BMI = weight kg / height m2);
- Within 6 months from the date of signing the informed consent to the end of the trial, female subjects agreed to take reliable measures to avoid pregnancy and ensure no birth plan, while male subjects agreed to take reliable measures to avoid pregnancy and ensure no birth plan;
- Willing to participate in the study and sign a written informed consent, able to communicate well with the researchers, and agreed to follow the requirements of the trial protocol and follow-up on schedule.
Exclusion Criteria:
- Participated in other drug clinical trials within 3 months before screening;
- Have any clinical history of serious diseases or are suffering from related diseases, including but not limited to digestive system (such as diarrhea, vomiting, inflammatory bowel disease, hemorrhoids, acute gastritis, peptic ulcer, acute and chronic gastrointestinal disorders with obvious digestive and absorption disorders), cardiovascular system, respiratory system, urinary system, musculoskeletal system, endocrine system, gastrointestinal tract diseases, etc Diseases of nervous and mental system, blood system, immune system, etc; A history of any disease or thrombotic disease or vascular malformation that increases the risk of bleeding; Patients with dysphagia;
- Allergic constitution, known allergic to test drug ingredients or allergic history to any drug or food (mango, shrimp, crab, lobster, etc.) or pollen allergy history;
- Those who smoke more than 5 cigarettes / day or the same amount of tobacco after inquiry, or who can not ban smoking during the trial period; Or alcohol consumption per week is equal to 14 units (1 units 25mL wine Baijiu / 100mL wine / 285mL beer), or those who can not prohibit alcohol during the test period;
- Have a history of drug abuse or drug abuse;
- Within 6 months, there were fertility planning, sperm donation and egg donation planning;
- Patients with lactose intolerance (those who have had diarrhea after drinking milk);
- Those who have special requirements for diet and cannot accept unified diet;
- Blood donors or massive blood loss (≥ 400ml), EPO treatment, blood transfusion or use of blood products within 3 months before screening;
- Those vaccinated within 8 weeks before screening or during the study period;
- There was a history of acupuncture and blood sickness; Or with orthostatic hypotension;
- Those who have participated in and used the trial drug;Those who have used any prescription drug, over-the-counter drug, Chinese herbal medicine, vitamins or health care products within 14 days before screening and whose time is less than 5 half-life of the drug or less than 2 weeks (whichever is the longest);
- The serum pregnancy test of lactating and pregnant women, or female volunteers of childbearing age was positive;
- The results of physical examination, chest X-ray, color Doppler ultrasound, electrocardiogram and laboratory examination were abnormal and clinically significant; Or hemoglobin of male subjects was more than 175.0 g / L; Or hemoglobin of female subjects was more than 150.0 g / L; Or hemoglobin of male and female were less than 113g / L;
- Within 48 hours before enrollment, those who took any special diet that affected the absorption, distribution, metabolism and excretion of drugs, including pitaya, mango, grapefruit, lime, carambola or food or drink prepared from them, chocolate, and any food or drink containing caffeine;
- Urine drug screening test was positive;
- Alcohol breath test was positive within 24 hours before administration;
- The researchers think that there are other cases that are not suitable for the trial.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Part 1: Single Dose Escalation SSS17
Escalating doses of SSS17, single dose administration
|
SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH).
It is being developed for the treatment of anemia in patients with chronic kidney disease.
|
|
Komparator placebo: Part 1: Single Dose Escalation matching Placebo
Escalating doses of matching placebo, single dose administration
|
Dopasowane placebo.
|
|
Eksperymentalny: Part 2: Multiple Dose Escalation SSS17
Escalating doses of SSS17, multiple dose administration
|
SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH).
It is being developed for the treatment of anemia in patients with chronic kidney disease.
|
|
Komparator placebo: Part 2: Multiple Dose Escalation matching Placebo
Escalating doses of matching placebo, multiple dose administration
|
Dopasowane placebo.
|
|
Eksperymentalny: Part 3: Treatment Sequence 1 (A to B)
The subjects in the first cycle received oral administration of SSS17 on an empty stomach, and subjects in the second cycle received oral administration of SSS17 after a high-fat meal
|
SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH).
It is being developed for the treatment of anemia in patients with chronic kidney disease.
|
|
Eksperymentalny: Part 3: Treatment Sequence 2 (B to A)
The subjects in the first cycle received oral administration of SSS17 after a high-fat meal, and the subjects in the second cycle received oral administration of SSS17 on an empty stomach
|
SSS17 is a novel small molecule compound which stimulates erythropoiesis through inhibition of hypoxiainducible factor- prolyl hydroxylases( HIF-PH).
It is being developed for the treatment of anemia in patients with chronic kidney disease.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Part 1: AEs
Ramy czasowe: Baseline up to Days 15
|
Assessment AEs by frequency and severity in the part 1
|
Baseline up to Days 15
|
|
Part 1: Maximum plasma concentration (Cmax) of SSS17
Ramy czasowe: Up to 336 hours post-dose
|
Plasma samples will be collected and Cmax will be assessed in the part 1
|
Up to 336 hours post-dose
|
|
Part 1: Area under the concentration-time curve (AUC) of plasma concentration of SSS17
Ramy czasowe: Up to 336 hours post-dose
|
Plasma samples will be collected and the AUC from zero to infinity will be assessed in the part 1
|
Up to 336 hours post-dose
|
|
Part 1: Time-to-Cmax (Tmax) of SSS 17
Ramy czasowe: Up to 336 hours post-dose
|
Plasma samples will be collected and the Tmax will be assessed from the concentration-time curve in the part 1
|
Up to 336 hours post-dose
|
|
Part 1: Elimination terminal half-life (t1/2) of SSS17
Ramy czasowe: Up to 336 hours post-dose
|
Plasma samples will be collected and the t1/2 will be assessed in the part 1
|
Up to 336 hours post-dose
|
|
Part 1: . Total amount of SSS17 excreted in urine over 72 hours (Ae0-72)
Ramy czasowe: Up to 72 hours post-dose
|
Urine sample will be collected at pre-specified intervals and Ae0-72 will be assessed in the part 1
|
Up to 72 hours post-dose
|
|
Part 1: Fraction of SSS17 excretion during each collection interval (Fe0-72)
Ramy czasowe: Up to 72 hours post-dose
|
Urine sample will be collected at pre-specified intervals and Fe0-72 will be assessed in the part 1
|
Up to 72 hours post-dose
|
|
Part 1: Renal clearance (CLR) of SSS17
Ramy czasowe: Up to 72 hours post-dose
|
Urine sample will be collected at pre-specified intervals and CLR will be assessed in the part 1
|
Up to 72 hours post-dose
|
|
Part 2: AEs
Ramy czasowe: Up to Days 33 or 57
|
Assessment AEs by frequency and severity in the part 2
|
Up to Days 33 or 57
|
|
Part 2: Steady state minimal concentration (Css_min) of SSS17
Ramy czasowe: Up to Days 33 or 57
|
Plasma samples will be collected and Css_min will be assessed in the part 2
|
Up to Days 33 or 57
|
|
Part 2: Steady state maximum concentration (Css_max) of SSS17
Ramy czasowe: Up to Days 33 or 57
|
Plasma samples will be collected and Css_max will be assessed in the part 2
|
Up to Days 33 or 57
|
|
Part 2: Steady state average concentration (Css_av) of SSS17
Ramy czasowe: Up to Days 33 or 57
|
Plasma samples will be collected and Css_av will be assessed in the part 2
|
Up to Days 33 or 57
|
|
Part 2: Area under the concentration-time curve of plasma concentration of SSS17 within the interval of administration after reaching steady state (AUC0-τ)
Ramy czasowe: Up to Days 33 or 57
|
Plasma samples will be collected and the AUC from zero to τ will be assessed
|
Up to Days 33 or 57
|
|
Part 3: Maximum plasma concentration (Cmax) of SSS17
Ramy czasowe: Up to Days 44
|
Plasma samples will be collected and Cmax will be assessed in the part 3
|
Up to Days 44
|
|
Part 3: Area under the concentration-time curve (AUC) of plasma concentration of SSS17
Ramy czasowe: Up to Days 44
|
Plasma samples will be collected and the AUC from zero to infinity will be assessed in the part 3
|
Up to Days 44
|
|
Part 3: Time-to-Cmax (Tmax) of SSS 17
Ramy czasowe: Up to Days 44
|
Plasma samples will be collected and the Tmax will be assessed from the concentration-time curve in the part 3
|
Up to Days 44
|
|
Part 3: Elimination terminal half-life (t1/2) of SSS17
Ramy czasowe: Up to Days 44
|
Plasma samples will be collected and the t1/2 will be assessed in the part 3
|
Up to Days 44
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Part 1: EPO concentrations
Ramy czasowe: Up to 168 hours post-dose
|
Change of EPO concentrations from baseline following SSS17 in the part 1
|
Up to 168 hours post-dose
|
|
Part 1: VEGF concentrations
Ramy czasowe: Up to 168 hours post-dose
|
Change of VEGF concentrations from baseline following SSS17 in the part 1
|
Up to 168 hours post-dose
|
|
Part 1: Change of hepcidin from baseline
Ramy czasowe: Up to 168 hours post-dose
|
Change of serum hepcidin concentrations from baseline following SSS17 in the part 1
|
Up to 168 hours post-dose
|
|
Part 1: Change of RTC from baseline
Ramy czasowe: Baseline up to Days 15
|
Change of RTC from baseline following SSS17 in the part 1
|
Baseline up to Days 15
|
|
Part 1: Change of RBC from baseline
Ramy czasowe: Baseline up to Days 15
|
Change of RBC from baseline following SSS17 in the part 1
|
Baseline up to Days 15
|
|
Part 1: Change of Hgb from baseline
Ramy czasowe: Baseline up to Days 15
|
Change of Hgb from baseline following SSS17 in the part 1
|
Baseline up to Days 15
|
|
Part 2: EPO concentrations
Ramy czasowe: Up to Days 33 or 57
|
Change of EPO concentrations from baseline following SSS17 in the part 2
|
Up to Days 33 or 57
|
|
Part 2: VEGF concentrations
Ramy czasowe: Up to Days 33 or 57
|
Change of VEGF concentrations from baseline following SSS17 in the part 2
|
Up to Days 33 or 57
|
|
Part 2: Change of hepcidin from baseline
Ramy czasowe: Up to Days 33 or 57
|
Change of serum hepcidin concentrations from baseline following SSS17 in the part 2
|
Up to Days 33 or 57
|
|
Part 2: Change of RTC from baseline
Ramy czasowe: Baseline up to Days 33 or 57
|
Change of RTC from baseline following SSS17 in the part 2
|
Baseline up to Days 33 or 57
|
|
Part 2: Change of RBC from baseline
Ramy czasowe: Baseline up to Days 33 or 57
|
Change of RBC from baseline following SSS17 in the part 2
|
Baseline up to Days 33 or 57
|
|
Part 2: Change of Hgb from baseline
Ramy czasowe: Baseline up to Days 33 or 57
|
Change of Hgb from baseline following SSS17 in the part 2
|
Baseline up to Days 33 or 57
|
|
Part 3: AEs
Ramy czasowe: Up to Days 44
|
Assessment AEs by frequency and severity in the part 3
|
Up to Days 44
|
|
Part 3: EPO concentrations
Ramy czasowe: Up to Days 44
|
Change of EPO concentrations from baseline following SSS17 in the part 3
|
Up to Days 44
|
|
Part 3: VEGF concentrations
Ramy czasowe: Up to Days 44
|
Change of VEGF concentrations from baseline following SSS17 in the part 3
|
Up to Days 44
|
|
Part 3: Change of hepcidin from baseline
Ramy czasowe: Up to Days 44
|
Change of serum hepcidin concentrations from baseline following SSS17 in the part 3
|
Up to Days 44
|
|
Part 3: Change of RTC from baseline
Ramy czasowe: Baseline up to Days 44
|
Change of RTC from baseline following SSS17 in the part 3
|
Baseline up to Days 44
|
|
Part 3: Change of RBC from baseline
Ramy czasowe: Baseline up to Days 44
|
Change of RBC from baseline following SSS17 in the part 3
|
Baseline up to Days 44
|
|
Part 3: Change of Hgb from baseline
Ramy czasowe: Baseline up to Days 44
|
Change of Hgb from baseline following SSS17 in the part 3
|
Baseline up to Days 44
|
Współpracownicy i badacze
Współpracownicy
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Oczekiwany)
Ukończenie studiów (Oczekiwany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- SYSS-SSS17-UND-I-02
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .